ioversol

Trade name: optiray

Small moleculeapprovedImaging agent

Approved

Dec 30, 1988

Ioversol is an organoiodine compound that used as a contrast medium. It features both a high iodine content, as well as several hydrophilic groups. It is indicated in adults for peripheral and coronary arteriography and left ventriculography, for excretory urography and computed tomography. Injections of contrast media are often associated with sensations of warmth and pain. Renal toxicity has been reported in a few patients with liver dysfunction who were given oral cholecystographic agents followed by intravascular contrast agents. — NCATS

Clinical trial activity

8 trials · 11 clinical orgs · 2 marketing orgs

Phase 1

Phase 2

Phase 3

Phase 4

Earliest trial started Jun 1, 2006 (NCT00335101)

Timeline

1980s

Dec 30, 1988
Liebel-Flarsheim — Earliest FDA Approval
Dec 30, 1988
Liebel-Flarsheim — NDA Secondary Org
Dec 30, 1988
Liebel-Flarsheim — NDA Organization

1990s

May 29, 1998
International Minerals and Chemical Corporation — NDA Secondary Org

2010s

Jan 1, 2014
Earliest Phase 1 Sponsor(trial)

2020s

Jan 1, 2024
Earliest Phase 3 Sponsor(trial)

Indications

Approved for

Studied for

Mechanism of action

contrast mediumRadiopaque
contrast medium radiopaque

Approval history

approvedDec 30, 1988

Chemistry & pharmacology

Loading structure…

SMILES

OCCN(C(=O)CO)C1=C(I)C(C(=O)NCC(O)CO)=C(I)C(C(=O)NCC(O)CO)=C1I

Mol. weight: 807.1113 g/mol
Lipinski Ro5: 2 violation(s)
Rule of 3: No
Chirality: Racemic Mixture
Inorganic: No
Polymer: No
Delivery: Parenteral
Availability: Prescription Only

Oral

Parenteral

Yes

Topical

Black box warning

Sources

Also known as

ioversol
ioversol
ioversol
ioversol
ioversol
ioversol
ioversol
ioversol
ioversol
ioversol
joversol
mp-328
mp-328
mp-328
n,n'-bis (2,3-dihydroxypropyl)-5-[n-(2-hydroxyethyl) -glycolamido] -2,4,6-triiodoisophthalamide
n,n'-bis (2,3-dihydroxypropyl)-5-[n-(2-hydroxyethyl) -glycolamido] -2,4,6-triiodoisophthalamide
optiray
optiray
optiray
optiray
optiray
optiray
optiray 160
optiray 160
optiray 240
optiray 240
optiray 300
optiray 300
optiray 300
optiray 320
optiray 320
optiray 320
optiray 350
optiray 350

Clinical trials

NCT ID	Phase	Start date	Sponsor(s)
NCT06656988	Phase 3	Nov 30, 2024	University of Leipzig
NCT05206331	Phase 4	Feb 1, 2022	National Cancer Institute (NCI), University of Pittsburgh
NCT04764292	Phase 4	Feb 15, 2021	PA Breast Cancer Coalition, University of Pittsburgh
NCT04024514	N/A	Aug 31, 2019	Riyeon Pharmaceuticals, Seoul National University
NCT03631771	Phase 4	Feb 28, 2019	Bayer, Duke University, General Electric
NCT02117115	Early Phase 1 (Phase 1)	Jun 1, 2014	Washington University in St. Louis
NCT00793182	Phase 4	Jan 1, 2009	Mallinckrodt
NCT00335101	Phase 4	Jun 1, 2006	General Electric

Showing 8 of 8 trials

Page 1 / 1

Organizations

Research & Development (11)

Organization	Org type	Trials	As lead sponsor	Phases	Earliest year
General Electric	For profit	2	2	1	2006
University of Pittsburgh	Academic/Hospital	2	2	1	2021
Bayer	For profit	1	0	1	2019
Duke University	Academic/Hospital	1	0	1	2019
Mallinckrodt	For profit	1	1	1	2009
National Cancer Institute (NCI)	Government	1	0	1	2022
PA Breast Cancer Coalition	Academic/Hospital	1	0	1	2021
Riyeon Pharmaceuticals	For profit	1	0	1	2019
Seoul National University	Academic/Hospital	1	1	1	2019
University of Leipzig	Academic/Hospital	1	1	1	2024
Washington University in St. Louis	Academic/Hospital	1	1	1	2014

11 organizations

Page 1 / 1

Marketing (3)

Organization	Org type	Relationship	Date
International Minerals and Chemical Corporation	For profit	NDA2	May 29, 1998
Liebel-Flarsheim	For profit	NDA2	Dec 30, 1988
Liebel-Flarsheim	For profit	NDA	Dec 30, 1988